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Abstract:
Rivaroxaban is one of  the new anti-coagulants that inhibit Factor Xa and rarely cause rectus sheath hematoma and retroperitone-
al haemorrhage which are uncommon, life-threatening complications.  Here is a case of  an elderly patient on rivaroxaban therapy 
for the stroke prevention in non-valvular atrial fibrillation who developed rectus sheath hematoma and retroperitoneal bleeding.
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Introduction
Recently,  new oral anticoagulants (NOACs) have begun 
to be used as the alternatives of  warfarin in non-valvu-
lar atrial fibrillation (AF). In general, NOACs may offer 
a significant advantage over warfarin for most patients. 
Relative to warfarin, NOACs are as effective or superior 
in the prevention of  stroke or embolic events and unlike 
warfarin, do not require frequent laboratory monitoring. 
However, in situations requiring rapid reversal of  anti-
coagulation such as majör bleeding, there are no specific 
antidotes1.
With expanding avenues of  NOACs use, the complica-
tions associated with these drugs are also increasing. NO-
ACs are associated with a decreased risk of  intracranial 
hemorrhage, but these agents may be associated with a 
slightly increased risk of  gastrointestinal bleeding relative 
to warfarin2. Also, formation of  rectus sheath hemato-
ma (RSH) and retroperitoneal hematoma are other such 
severe complications with high risk of  mortality and re-
quires a close follow up3.
Rivaroxaban is a fast acting new oral anticoagulant that 
uses orally and directly inhibits Factor Xa. It is indicated 
for the prophylaxis and treatment of  deep venous throm-
bosis and stroke prevention in non-valvular AF4,5. Here 
is a case of  rivaroxaban associated RSH and minor retro-
peritoneal bleeding in a patient initiated on anti-coagula-
tion for non-valvular AF.
 
Case Report
A 76 year old female with a history of  hypertension, di-
abetes mellitus, hyperlipidemia, hypothyroidism, asthma 
and non-valvular AF presented to the emergency depart-
ment with complaints of  cough and acute onset severe 
abdominal pain in the left abdominal area with radiation 
to the back. On physical examination; she had wide ec-
chymotic area on anterior abdominal wall extending to 
the left lumbar region and widespread tenderness and 
voluntary defenses were present. There was no rebound 
tenderness Figure 1. Her blood pressure was 128/70 mm 
Hg, pulse 98 beats/minute, respiratory rate 18 breaths/
minute, and temperature 36.7°C.  Laboratory studies 
showed normal white blood cell count, hemoglobin of  
9.5 g/dL normal range 12-18.1 g/dl, hematocrit of  32.1% 
normal range 36%-53.7%, platelets of  296x103/mm3 nor-
mal range 140-400×103/mm3, normal international nor-
malized ratio, blood urea nitrogen of  39 mg/dL normal 
range 5-22 mg/dL, and normal creatinine. The computed 
tomography of  the abdomen with contrast showed left 
RSH measuring approximately 10×4×12 cm and minimal 
hemorrhagic areas in the retroperitoneum Figure 2.
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Wide ecchymotic area on anterior abdominal wall  
extending to the left lumbar region. 
 
 
Contrast CT scan image of abdomen. Image shows left rectus sheath  
hematoma and minor retroperitoneal bleeding area. 
As part of  a treatment for her non-valvular AF, the pa-
tient had been using rivaroxaban at a dose of  15 mg/day 
for the past three months. She had no history of  trauma 
and had not used any other drug that could account for 
the bleeding and hematoma formation.  Her daily drugs 
were as follows: diltiazem 90 mg/day mg, furosemide 40 
mg/day, rivaroxaban 15 mg/day, metformin 2 gr/day, 
levothyroxine sodium 100 μg/day, budesonide/formo-
terol 400 μg/12 μg twice a day  and salbutamol as needed.
Rivaroxaban was discontinued and the patient was mon-
itored for extension of  the hematoma. Two units of  
packed red blood cells and fresh frozen plasma were 
administered.  She remained hemodynamically stable 
and  hemoglobin values were regularly controlled and 
showed no significant decrease.  After 7 days, she was 
discharged home with dabigatran at the dose of  110 mg 
twice a day instead of  rivaroxaban. 
At her follow-up visit 1 week later, complaints and 
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AHA guidelines recommend warfarin evidence level I-A, 
dabigatran evidence level I-B,rivaroxaban evidence level 
IIa-B, and apixaban evidence level I-A as preferred agents 
to prevent the risk of  thromboembolism in AF6,4. Never-
theless, rarely, these drugs can lead to serious haemorrhag-
ic complications. RSH and retroperitoneal haemorrhage 
are  rare but important complications of  anticoagulant 
therapy and there have been rare reported cases develop-
ing hemorrhage while receiving rivaroxaban7,8,9
 Although RSH is rare, there is a well-defined pathogen-
esis, clinic and treatment3. There are superior and inferi-
or epigastric venules along the posterior border of  the 
rectus sheath, Rupture of  these vessels or rupture of  the 
rectus abdominis results in RSH9.  Spontaneous sheath 
hematomas may occur in elderly humans as the elastici-
ty of  the epigastric veins decreases due to atheromatous 
wall changes10. Possible risk factors include trauma, rap-
id and sudden position changes, anticoagulation thera-
py, new history surgical operation, acute exacerbation 
of  asthma-chronic obstructive pulmonary disease with 
cough attacks, injections and pregnancy11.  Rectus sheath 
hematomas are often self-limited, so treatment is conser-
vative. But, surgical treatment is indicated in hematomas 
that cause hemodynamic disorders and complicated he-
matomas peritoneal rupture, infection, etc.13.
There is no clear antidote to reverse the effects of  rivar-
oxaban. The average terminal half-life of  rivaroxaban is 
7-11 hours, so conservative treatment for bleeding events 
will be effective for the majority of  patients7. Such hema-
toma treatment involves regular monitoring of  hemoglo-
bin levels and, if  necessary, supportive treatment based 
on erythrocyte transfusion. Many studies have shown that 
prothrombin complex concentration may be useful in re-
versing the effects of  rivaroxaban. Another option would 
be to use recombinant Factor VIIa to reduce bleeding14.
It is essential to choose the appropriate patients for treat-
ment with NOACs to reduce the risk of  adverse events. 
Also, the most important point in terms of  clinicians is 
appropriate  dose  selection in patients  for new genera-
tion agents;  because there is not yet an antidote that can 
be used when there is major bleeding due to the use of  
the new generation oral anticoagulant15. For Rivaroxaban; 
patients with moderate to severe renal impairment (creat-
inine clearence) CrCl 15-49, a dose adjustment to 15 mg 
once daily is recommended, but dose adjustment forbody 
weight or elderly age is not recommended15.
We recommend that clinicians choose the appropriate pa-
tients, select appropriate  dose  and become aware of  the 
potential for rare and serious bleeding complications of  
anticoagulants and identify the need for early recognition 
and prompt management.
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